USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: OPTIMUM THERAPEUTICS, LLC
City: San Diego
State: CA
Zip+4: 92121
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://optimumtx.com
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,353,175.00 7
SBIR Phase II $2,217,457.00 2

Award List:

Apoptosis Inducing to Enhance Tumor Targeting

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ze Lu
Award Amount: $495,504.00
Abstract:
DESCRIPTION (provided by applicant): Management of patients with metastatic pancreatic and ovarian cancer faces unmet needs. These patients usually present with multiple solid tumors and malignant ascites in the peritoneal cavity that are not adequately managed by systemic intravenous (iv)… More

Bladder Tumor Targeting by Intravesical Paclitaxel

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tengkuang Yeh
Award Amount: $600,314.00
Abstract:
DESCRIPTION (provided by applicant): Superficial bladder cancer is often managed by transurethral surgical resection, followed by intravesical chemotherapy. Mitomycin C (MMC) and doxorubicin are among the most commonly used drugs. Through a series of preclinical and clinical studies, our research… More

FGFs to Broadly Protect Chemotherapy-Induced Alopecia

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ze Lu
Award Amount: $197,840.00
Abstract:
DESCRIPTION (provided by applicant): Chemotherapy-induced alopecia (CIA) is one of the most common and psychologically distressing side effects of cancer chemotherapy. CIA consists of hair loss, reduced hair growth, and structural abnormalities in the newly grown hair. Devastation due to CIA is… More

Tumor-priming Microparticles for Pancreatic Cancer

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ze Lu – (614) 688-5885
Award Amount: $841,754.00
Abstract:
DESCRIPTION (provided by applicant): Patients with advanced pancreatic cancer have a bleak prognosis, with a median survival time of less than 6 months. These patients usually present with multiple solid tumors in the peritoneal cavity; systemic intravenous (iv) therapy with various chemotherapeutic… More

rTS Signaling Mimetics As Novel Cancer Therapeutics

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jie Wang
Award Amount: $163,657.00
Abstract:
DESCRIPTION (provided by applicant): The Dolnick laboratory recently reported a novel signaling pathway governing both the level of thymidylate synthase protein (TS) and the cytoskeleton function in human cancer cells. This pathway plays an important role in determining cell proliferation and… More

Intraperitoneal Tumor-Targeting Chemo-gene Therapy

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $248,174.00
Abstract:
DESCRIPTION (provided by applicant): Cancer arising from organs within the peritoneal cavity (pancreatic, ovarian, colorectal, gastric, liver) accounts for more than 200,000 new cases annually. The cavity is also a common site for metastasis of advanced ca ncer originating from extra-abdominal… More

Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,375,703.00
Abstract:
DESCRIPTION (provided by applicant): Bladder cancer is the fourth most common cancer in the United States. In 2007, about 67,160 new cases of bladder cancer will be diagnosed and 13,750 patients will die of these diseases. Transitional cell carcinoma accou nts for more than 90% of bladder cancers.… More

Intra-bladder MMC and suramin for nonmuscle-invading and locally advanced bladder ca

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ze Lu – 614-688-5885
Award Amount: $303,226.00
Abstract:
DESCRIPTION (provided by applicant): Bladder cancer is the fourth most common cancer in the US. Due to its easily accessible location and relatively early diagnosis, bladder cancer is one of the least lethal cancers and there are ~540,000 survivors in theUS. At presentation, gt80% of bladder tumors… More

Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ze Lu – 858-455-1155
Award Amount: $344,460.00
Abstract:
DESCRIPTION (provided by applicant): Bladder cancer is the fourth most common cancer in the US. At presentation, gt80% of bladder tumors are organ-confined, separated clinically into two groups. The most common group is the nonmuscle-invading tumors, accounting for about 70-80% of cases. This group… More